Antibody Response to Symptomatic Infection With SARS‐CoV‐2 Omicron Variant Viruses, December 2021

Antibody Response to Symptomatic Infection With SARS‐CoV‐2 Omicron Variant Viruses, December 2021–June 2022

Published:2024-07 Issue:7 Volume:18 Page:
ISSN:1750-2640
Container-title:Influenza and Other Respiratory Viruses
language:en
Short-container-title:Influenza Resp Viruses

Author:

Sandford Ryan¹²³^ORCID,Yadav Ruchi¹,Noble Emma K.¹²,Sumner Kelsey¹^ORCID,Joshi Devyani¹,Tartof Sara Y.⁴⁵,Wernli Karen J.⁶,Martin Emily T.⁷^ORCID,Gaglani Manjusha⁸⁹,Zimmerman Richard K.¹⁰,Talbot H. Keipp¹¹,Grijalva Carlos G.¹¹,Belongia Edward A.¹²^ORCID,Carlson Christina¹,Coughlin Melissa¹,Flannery Brendan¹,Pearce Brad³,Rogier Eric¹

Affiliation:

1. Centers for Disease Control and Prevention Atlanta Georgia USA

2. Oak Ridge Institute for Science and Education Oak Ridge Tennessee USA

3. Rollins School of Public Health Atlanta Georgia USA

4. Department of Research & Evaluation Kaiser Permanente Southern California Yorba Linda California USA

5. Department of Health Systems Science Kaiser Permanente Bernard J. Tyson School of Medicine Pasadena California USA

6. Kaiser Permanente Washington Health Research Institute Seattle Washington USA

7. University of Michigan School of Public Health Ann Arbor Michigan USA

8. Baylor Scott & White Health Temple Texas USA

9. Texas A&M University College of Medicine Temple Texas USA

10. University of Pittsburgh Pittsburgh Pennsylvania USA

11. Vanderbilt University Medical Center Nashville Tennessee USA

12. Marshfield Clinic Research Institute Marshfield Wisconsin USA

Abstract

ABSTRACTWe describe humoral immune responses in 105 ambulatory patients with laboratory‐confirmed SARS‐CoV‐2 Omicron variant infection. In dried blood spot (DBS) collected within 5 days of illness onset and during convalescence, we measured binding antibody (bAb) against ancestral spike protein receptor binding domain (RBD) and nucleocapsid (N) protein using a commercial multiplex bead assay. Geometric mean bAb concentrations against RBD increased by a factor of 2.5 from 1258 to 3189 units/mL and by a factor of 47 against N protein from 5.5 to 259 units/mL between acute illness and convalescence; lower concentrations were associated with greater geometric mean ratios. Paired DBS specimens may be used to evaluate humoral response to SARS‐CoV‐2 infection.

Funder

Centers for Disease Control and Prevention

National Institutes of Health

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/irv.13339

Reference22 articles.

1. Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine

2. Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial

3. Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial

4. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

5. Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021